Inactive Instrument

Press Releases Alder BioPharmaceuticals, Inc.

Equities

US0143391052

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Lundbeck and Alder BioPharmaceuticals announce updated information in the tender offer materials filed with SEC	19-10-11	GL
Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine	19-10-10	GL
WeissLaw LLP Investigates Alder Biopharmaceuticals, Inc.	19-09-17	PR
Lundbeck to acquire Alder BioPharmaceuticals – a company committed to transforming migraine treatment and prevention – in a transaction valued at up to USD 1.95 billion net of cash	19-09-16	GL
Alder BioPharmaceuticals® to Showcase Data from Migraine Prevention Portfolio at 19th Congress of the International Headache Society	19-09-05	GL
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	19-08-30	GL
Alder BioPharmaceuticals® to Present at Two Upcoming September Investor Conferences	19-08-28	GL
Alder BioPharmaceuticals® Reports Second Quarter 2019 Financial and Operating Results	19-08-06	GL
Alder BioPharmaceuticals® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	19-08-02	GL
Alder BioPharmaceuticals® to Host Conference Call to Discuss Second Quarter 2019 Financial and Operating Results	19-07-30	GL
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	19-07-26	GL
Alder BioPharmaceuticals® Presents New Data on Migraine-Free Months, Migraine Severity and Quality of Life, Demonstrating Eptinezumab’s Clinical Profile for Migraine Prevention	19-07-11	GL
Alder BioPharmaceuticals® to Showcase 14 New Data Presentations Demonstrating Eptinezumab’s Migraine Prevention and Quality of Life Impact at American Headache Society Meeting	19-07-08	GL
Alder BioPharmaceuticals® to Webcast Upcoming Breakfast Symposium with Key Opinion Leaders	19-06-19	GL
Alder BioPharmaceuticals® to Present at BMO Capital Markets 2019 Prescription for Success Healthcare Conference	19-06-18	GL
Alder BioPharmaceuticals® Presents New Data Demonstrating Consistent, Early and Robust Prevention with Eptinezumab for Episodic and Chronic Migraine across Four Clinical Trials	19-05-06	GL
Alder BioPharmaceuticals® to Host Conference Call to Discuss First Quarter 2019 Financial and Operating Results	19-04-26	GL
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	19-04-26	GL
U.S. Food and Drug Administration Accepts Biologics License Application for Eptinezumab	19-04-22	GL
Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	19-04-19	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Alder BioPharmaceuticals, Inc.

Equities

US0143391052

Press Releases

Filters